Clinical and laboratory characteristics at diagnosis of the 962 patients with PV or ET according to their JAK2 617V>F mutational state
| . | Polycythemia vera, n = 323 . | Essential thrombocythemia, n = 639 . | |||
|---|---|---|---|---|---|
| Hetero . | Homo . | WT . | Hetero . | Homo . | |
| Patients, no. (%) | 219 (67.8) | 104 (32.2) | 257 (40.2) | 368 (57.6) | 14 (2.2) |
| Females, no. (%) | 97 (44.3) | 50 (48.1) | 169 (65.8) | 259 (70.4) | 9 (64.3) |
| Age, y* | 59.8 ± 13.8 | 59.8 ± 10.8 | 46.5 ± 16.7‡ | 52.4 ± 17.1 | 56.3 ± 21.0 |
| Disease duration, y*† | 5.3 ± 4.8§ | 7.8 ± 5.8 | 7.1 ± 5.8 | 6.5 ± 5.4 | 8.6 ± 4.5 |
| WBC, ×109/L* | 10.4 ± 3.3§ | 12.0 ± 4.3 | 8.4 ± 3.2‖ | 9.3 ± 2.7‖ | 14.2 ± 6.1 |
| Hct, %* | 53.6 ± 6.1§ | 55.9 ± 6.9 | 40.7 ± 3.8¶ | 43.1 ± 4.2 | 43.9 ± 4.4 |
| Platelet count, ×1012/L* | 567 ± 248§ | 473 ± 198 | 939 ± 422 | 787 ± 261 | 808 ± 336 |
| Splenomegaly, no. (%) | 94 (44.8)¶ | 57 (58.8) | 37 (21.9)§ | 77 (27.6)§ | 8 (72.7) |
| 12–15 cm | 64 (30.5) | 35 (36.1) | 35 (20.7) | 66 (23.7) | 5 (45.5) |
| Larger than 15 cm | 30 (14.3) | 22 (22.7) | 2 (1.2)‖ | 11 (3.9)§ | 3 (27.3) |
| Pruritus, no. (%) | 61 (28.0)§ | 43 (42.2) | 10 (5.3) | 21 (7.1) | 1 (9.1) |
| Systemic symptoms, no. (%) | 29 (13.2) | 21 (20.4) | 12 (6.3) | 20 (6.8) | 2 (18.2) |
| . | Polycythemia vera, n = 323 . | Essential thrombocythemia, n = 639 . | |||
|---|---|---|---|---|---|
| Hetero . | Homo . | WT . | Hetero . | Homo . | |
| Patients, no. (%) | 219 (67.8) | 104 (32.2) | 257 (40.2) | 368 (57.6) | 14 (2.2) |
| Females, no. (%) | 97 (44.3) | 50 (48.1) | 169 (65.8) | 259 (70.4) | 9 (64.3) |
| Age, y* | 59.8 ± 13.8 | 59.8 ± 10.8 | 46.5 ± 16.7‡ | 52.4 ± 17.1 | 56.3 ± 21.0 |
| Disease duration, y*† | 5.3 ± 4.8§ | 7.8 ± 5.8 | 7.1 ± 5.8 | 6.5 ± 5.4 | 8.6 ± 4.5 |
| WBC, ×109/L* | 10.4 ± 3.3§ | 12.0 ± 4.3 | 8.4 ± 3.2‖ | 9.3 ± 2.7‖ | 14.2 ± 6.1 |
| Hct, %* | 53.6 ± 6.1§ | 55.9 ± 6.9 | 40.7 ± 3.8¶ | 43.1 ± 4.2 | 43.9 ± 4.4 |
| Platelet count, ×1012/L* | 567 ± 248§ | 473 ± 198 | 939 ± 422 | 787 ± 261 | 808 ± 336 |
| Splenomegaly, no. (%) | 94 (44.8)¶ | 57 (58.8) | 37 (21.9)§ | 77 (27.6)§ | 8 (72.7) |
| 12–15 cm | 64 (30.5) | 35 (36.1) | 35 (20.7) | 66 (23.7) | 5 (45.5) |
| Larger than 15 cm | 30 (14.3) | 22 (22.7) | 2 (1.2)‖ | 11 (3.9)§ | 3 (27.3) |
| Pruritus, no. (%) | 61 (28.0)§ | 43 (42.2) | 10 (5.3) | 21 (7.1) | 1 (9.1) |
| Systemic symptoms, no. (%) | 29 (13.2) | 21 (20.4) | 12 (6.3) | 20 (6.8) | 2 (18.2) |
Hetero indicates patients heterozygous for the JAK2 617V>F mutation; Homo, patients homozygous for the JAK2 617V>F mutation; WT, patients wild-type for the JAK2 617V>F mutation; and WBC, white blood cell count.
Mean ± SD.
Time from diagnosis to last follow-up.
P < .05 in the comparison with heterozygous patients.
P ≤ .01 in the comparison of homozygous patients to either wild-type (in case of ET) or the heterozygous counterpart.
P ≤ .001 in the comparison of homozygous patients to either wild-type (in case of ET) or the heterozygous counterpart.
P < .05 in the comparison of homozygous patients to either wild-type (in case of ET) or the heterozygous counterpart.